Practice-changing updates in the December 2019 release

Practice-changing updates in the December 2019 release

As well as including a comprehensive update to the Oral and Dental guidelines, the December 2019 release of eTG complete also includes the following practice-changing updates to other guidelines.


Antibiotic guidelines

Cardiovascular guidelines

  • A footnote has been added to acknowledge the recommendation to use the sexless CHA2DS2-VASc score to stratify stroke risk in patients with ‘nonvalvular’ atrial fibrillation in the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand clinical guidelines for the diagnosis and management of atrial fibrillation 2018. <>
  • The dosing of danaparoid for treatment of heparin-induced thrombocytopenia has been updated to align with the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) consensus statement on diagnosis and management of heparin-induced thrombocytopenia. <>

Dermatology guidelines

  • The management of primary oral mucocutaneous herpes has been updated to include currently available topical analgesics and anaesthetics. Episodic antiviral therapy for a minor recurrence in immunocompetent adults now includes a single dose of oral famciclovir.

Neurology guidelines

Psychotropic guidelines

  • A footnote to alert users to the discontinuation of trifluoperazine and fluphenazine has been added.
  • Sources of information for psychotropic drug use during pregnancy and while breastfeeding have been updated.